APITBIO, Inc.
June 17, 2025
Company Presentation
Platform for Therapeutics
154
APITBIO is an innovative biotech venture focused on antibody-based drug discovery, developing a pipeline of first-in-class monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs). Leveraging its proprietary human Fab antibody library and novel platforms for antibody discovery and BsAb construction, APITBIO also provides related services.
.png)
Company HQ City:
Songpa
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2018
Lead Product in Development:
1. Phase 1 clinical trial approval in Korea completed for a human antibody targeting L1CAM (CD171) overexpressed in various intractable solid tumors
2. Complete remission observed in animal studies of First-in-Class L1CAM ADC
CEO
Seon-Joo Yoon
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
Four
When you expect your next catalyst update?
The excellent biophysical properties of our novel antibodies, namely high productivity and low hydrophobicity, will be one of our next catalysts for developing ADCs.
What is your next catalyst (value inflection) update?
Within a year
Website
https://www.apitbio.com/
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}